12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rivaroxaban regulatory update

FDA approved an sNDA from Johnson & Johnson for Xarelto rivaroxaban to treat deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE. The oral Factor Xa inhibitor is marketed in the...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >